|
" Therapy for viral hepatitis and prevention of hepatocellular carcinoma. "
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
770853
|
| Doc. No
|
:
|
b590846
|
| Title & Author
|
:
|
Therapy for viral hepatitis and prevention of hepatocellular carcinoma.
|
| Publication Statement
|
:
|
[Place of publication not identified] : Springer, 2013
|
| ISBN
|
:
|
4431539778
|
|
|
:
|
: 9784431539773
|
| Contents
|
:
|
1 Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma.- 1.1 Opening Lecture: What is Accomplished and What is Needed.- 2 Lamivudine Therapy for Hepatitis B.- 2.1 New Anti-Virals Against Wild-Type and Lamivudine-Resistant Hepatitis B Virus.- 2.2 Lamivudine Therapy of Hepatitis B in Japan.- 2.3 Early Detection of Lamivudine Resistant Mutant in Chronic Hepatitis B Patients Using a Novel Sensitive Method.- 3 New Anti-Virals: HBV.- 3.1 New Antiviral Treatment for Chronic Hepatitis B.- 3.2 New Antiviral Therapy: Adefovir Dipivoxil for HBV.- 3.3 Development of Entecavir: Superior Therapy for the Management of Chronic Hepatitis B Viral Infection.- 4 Therapy for Hepatitis B and Prevention of HCC.- 4.1 Therapy of Hepatitis B and Prevention of Hepatocellular Carcinoma.- 4.2 Differences of Clinical Characteristics Among Japanese Patients with Hepatitis B Virus Genotypes B and C.- 5 HCV Replicon System.- 5.1 Establishment of a New Hepatitis C Virus-l b Replicon.- 5.2 Hepatitis C Virus Replication in Cell Culture.- 5.3 Characterization of the Interferon Alpha Response Against HCV in Hepatoma Cells.- 6 New Anti-Virals: HCV.- 6.1 Hepatitis C: Development of a Ribavirin Liver-Targeting Prodrug.- 6.2 HCV Replicon Inhibitors: Mode of Action and Resistance Mapping.- 7 Interferon Therapy for Hepatitis C.- 7.1 Interferon Treatment Not Only Reduces the Risk of Hepatocellular Carcinoma But Also Improves Mortality in Patients with Chronic Hepatitis C Showing Biochemical Response, Especially in Patients with Advanced Liver Fibrosis.- 7.2 Favorable Outcome of Patients with C-Viral Liver Disease Treated with Interferon.- 7.3 IFN Receptor and IFN Signals.- 8 Therapy for Hepatitis C and Prevention of HCC.- 8.1 Management and Treatment of Hepatitis C.- 8.2 Hepatitis C Virus and Hepatocellular Carcinoma.- 8.3 Randomized Trial of Post-Operative Interferon Therapy After Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma and Long-Term Outcome.- 8.4 Roles of Antiviral Therapy in Chronic Hepatitis C Patients Should be Different According to the Stages of Liver Disease Progression.- 8.5 Significance of Sustained Inflammation in the Development of HCC from HCV-Associated Cirrhotic Patients and the Prevention of HCC by Anti-Inflammatory Agents.- 9 Chemoprevention and Therapy for HCC.- 9.1 Chemoprevention of Hepatocellular Carcinoma with Retinoid.- 9.2 Vitamin K2Administration Improves the Prognoses of Patients with Hepatocellular Carcinoma Presenting High Levels of Serum Des-?-Carboxy Prothrombin.- 9.3 Combination Chemotherapy for Advanced Hepatocellular Carcinoma.- 9.4 Combined Intra-Arterial 5-Fluorouracil and Subcutaneous Interferon-Alpha Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombi in the Major Portal Branches.- 10 Transplantation for HBV and HCV.- 10.1 Liver Transplantation for Hepatitis B Virus-Related Liver Disease.- 10.2 Living Donor Liver Transplantation for Hepatitis B and C Cirrhosis.- 10.3 Living Donor Liver Transplantation for HBV-/HCV-Related Diseases.
|
| LC Classification
|
:
|
QR201.H46T447 2013
|
| |